Application Number		10561823	
Filing Date		2005-12-19	
First Named Inventor Joerge		en Hansen	
Art Unit		1632	
Examiner Name			
Attorney Docket Number		14455.880US01	
	Filing Date First Named Inventor Art Unit Examiner Name	Filing Date First Named Inventor Joerg Art Unit Examiner Name	

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	of cited Document		Releva		Lines where ges or Relev	
	1										
If you wisl	h to a	l dd additional U.S. Pater	ıt citatio	n inform	ation pl	l ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant Iment	Releva		Lines where	
	1	20060275877	A1	2006-12	2-07	Joergen Hans	en, et al.				
If you wisl	h to a	⊥ dd additional U.S. Publi	⊥ shed Ap	l plication	n citatio	ı n information p	olease click the Add	d button	Add		
				FOREIG	GN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patented Applicant of cited Document	e or V	vhere Rel	or Relevant	T5
	1	WO 03/048375	WO		A1	2003-06-12	Biotica Technology Limited				
	2	WO 01/79520	WO		A1	2001-10-25	Biotica Technology Limited				
	3	WO 01/40491	WO		A2	2001-06-07	Luminis Pty, Ltd.; R Veterinary and Ag.				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10561823		
Filing Date		2005-12-19		
First Named Inventor	Joerg	en Hansen		
Art Unit		1632		
Examiner Name				
Attorney Docket Number		14455.880US01		

	4	WO 03/066836	WO	A2	2003-08-14	E. I. DuPont De Nemours and Co.			
If you wis	h to a	dd additional Foreign P	atent Document	citation	information p	lease click the Add buttor	Add	1	
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
	1	QUIROS, L.M., et al.: "Two glycosyltransferases and a glycosidase are involved in oleandomycin modification during its biosynthesis by streptomyces antibioticus", MOLECULAR MICROBIOLOGY, BLACKWELL SCIENTIFIC, OXFORD, GB, vol. 28, no. 6, June 1998 (1998-06), pages 1177-1185, XP000858900; ISSN: 0950-382X; page 1181, right-hand column, paragraph 3 - page 1182, left-hand column, paragraph 1; figures 1, 7							
	2	RATY, K. et al.: "A gene cluster from streptomyces galilaeus involved in glycosylation of aclarubicin" MOLECULAR AND GENERAL GENETICS, vol. 264, no. 1-2, September 2000 (2000-09), pages 164-172, XP002304279; ISSN: 0026-8925; abstract							
	3	SANCHEZ, CESAR, et al.: "The biosynthetic gene cluster for the antitumor rebeccamycin: Characterization and generation of indolocarbazole derivatives" CHEMISTRY AND BIOLOGY (LONDON), vol. 9, no. 4, April 2002 (2002-04), pages 519-531, XP002304280; ISSN: 1074-5521; abstract; figures 1,3,4							
	4	ARANA, FRANCISCA E.: "Action of a beta-glucosidase in the curing of Vanilla" FOOD RESEARCH, ISSN: 0095-974X, vol. 8, 1943, pages 343-351, XP009024054 page 347, paragraph 3 - page 348, paragraph 1 page 348, paragraph 3; table 2 page 350, paragraph 4 abstract							
	5	ZHENG, ZUOXING, et al.: "Solid-State Bioconversion of Phenolics from Cranberry Pomace and Role of Lentinus edodes.betaGlucosidase" JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 48, no. 3, March 2000 (2000-03), pages 895-900, XP002267398 abstract; figure 6; table 2 page 898, column 2, paragraph 2 - page 899, column 1, paragraph 4							
	6	DAY, A. J., et al.: "Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 436, no. 1, 25 September 1998 (1998-09-25), pages 71-75, XP004258361 ISSN: 0014-5793 abstract; figure 1; table 1 page 74, column 1, paragraph 4.							
	7	CICEK, MUZAFFER et al.: "The aglycone specificity-determining sites are different in 2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one (DIMBOA)-glucosidase (maize.betaglucosidase) and dhurrinase (sorghum.betaglucosidase)" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 26, 30 June 2000 (2000-06-30), pages 20002-20011, XP002267399 abstract; figure 1 page 20002, column 2, paragraph 2 - page 20003, column 1, paragraph 1							
	8	BAK, S. et al.: "TRANSGENIC TOBACCO AND ARABIDOPSIS PLANTS EXPRESSING THE TWO MULTIFUNCTIONAL SORGHUM CYTOCHROME P450 ENZYMES, CYP79A1 AND CYP71E1, ARE CYANOGENIC AND ACCUMULATE METABOLITES DERIVED FROM INTERMEDIATES IN DHURRIN BIOSYNTHESIS" PLANT PHYSIOLOGY, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, US, vol. 123, August 2000 (2000-08), pages 1437-1448, XP001006399 ISSN: 0032-0889 cited in the application abstract; figure 1 page 1440,							
If you wish to add additional non-patent literature document citation information please click the Add button Add									

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10561823				
Filing Date		2005-12-19				
First Named Inventor	Joerge	en Hansen				
Art Unit		1632				
Examiner Name						
Attorney Docket Number		14455.880US01				

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10561823			
Filing Date		2005-12-19			
First Named Inventor	Joergen Hansen				
Art Unit		1632			
Examiner Name					
Attorney Docket Numb	er	14455.880US01			

		C	ERTIFICATION	STATEMENT				
Plea	ase see 37 CFR	R 1.97 and 1.98 to make the ap	propriate selection	on(s):				
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).							
OF	R							
	foreign patent after making rany individual	office in a counterpart foreigr easonable inquiry, no item of i	n application, and nformation conta	d, to the knowledge of tl iined in the information d	cited in a communication from a he person signing the certification lisclosure statement was known to filing of the information disclosure			
	See attached	certification statement.						
	Fee set forth in	n 37 CFR 1.17 (p) has been su	bmitted herewith	ı .				
×	None							
	SIGNATURE A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.							
Sigi	nature	/peterbscull/		Date (YYYY-MM-DD)	2007-01-12			
Nar	ne/Print	Peter B. Scull		Registration Number	37,932			
This	This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the							

public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria**,

VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.